Selected Publications
Ivaska J, Whelan RDH, Watson R and Parker PJ. PKCε controls the traffic of β1 integrins in motile cells. EMBO J 2002; 21: 3608-3619. PubMed PDF (UKPMC)
Ivaska J, Bosca L and Parker PJ. PKCε is a permissive link in integrin-dependent IFN-γ signalling that facilitates JAK phosphorylation of STAT1. Nat Cell Biol 2003; 5: 363-369. PubMed
Parkinson SJ, Good JA, Whelan RD, Whitehead P and Parker PJ. Identification of PKCζII: an endogenous inhibitor of cell polarity. EMBO J 2004; 23: 77-88. PubMed PDF (UKPMC)
Kermorgant S, Zicha D and Parker PJ. PKC controls HGF-dependent c-Met traffic, signalling and cell migration. EMBO J 2004; 23: 3721-3734. PubMed PDF (UKPMC)
Ivaska J, Vuoriluoto K, Huovinen T, Izawa I, Inagaki M and Parker P. PKCε-mediated phosphorylation of vimentin controls integrin recycling and motility. EMBO J 2005; 24: 3834-3845. PubMed PDF (UKPMC)
Primary Research Publications
2010
Cameron AJ, Parker PJ. Protein kinase C - a family of protein kinases, allosteric effectors or both?. Adv Enzyme Regul 2010; 50 (1):169-177. PubMed; DOI: 10.1016/j.advenzreg.2009.10.004.
Zwaenepoel K, Goris J, Erneux C, Parker PJ, Janssens V. Protein phosphatase 2A PR130/B ''alpha 1 subunit binds to the SH2 domain-containing inositol polyphosphate 5-phosphatase 2 and prevents epidermal growth factor (EGF)-induced EGF receptor degradation sustaining EGF-mediated signaling. FASEB J 2010; 24 (2):538-547. PubMed; DOI: 10.1096/fj.09-140228.
2009
Tuomi S, Mai A, Nevo J, Laine JO, Vilkki V, Ohman TJ, Gahmberg CG, Parker PJ, Ivaska J. PKC epsilon Regulation of an alpha(5) Integrin-ZO-1 Complex Controls Lamellae Formation in Migrating Cancer Cells. Sci Signal 2009; 2 (77):ra32. PubMed; DOI: 10.1126/scisignal.2000135.
Rosse C, Formstecher E, Boeckeler K, Zhao YM, Kremerskothen J, White MD, Camonis JH, Parker PJ. An aPKC-Exocyst Complex Controls Paxillin Phosphorylation and Migration through Localised JNK1 Activation. PLoS Biol 2009; 7 (11):e1000235. PubMed; DOI: 10.1371/journal.pbio.1000235.
Kostelecky B, Saurin AT, Purkiss A, Parker PJ, McDonald NQ. Recognition of an intra-chain tandem 14-3-3 binding site within PKC epsilon. EMBO Rep 2009; 10 (9):983-989. PubMed.
Cameron AJM, Escribano C, Saurin AT, Kostelecky B, Parker PJ. PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat Struct Mol Biol 2009; 16 (6):624-630. PubMed.
De Rycker M, Rigoreau L, Dowding S, Parker PJ. A High-Content, Cell-Based Screen Identifies Micropolyin, A New Inhibitor of Microtubule Dynamics. Chem Biol Drug Des 2009; 73 (6):599-610. PubMed; DOI: 10.1111/j.1747-0285.2009.00817.x.
Roffey J, Rosse C, Linch M, Hibbert A, McDonald NQ, Parker PJ. Protein kinase C intervention-the state of play. Curr Opin Cell Biol 2009; 21 (2):268-279. PubMed.
Saurin AT, Brownlow N, Parker PJ. Protein kinase C epsilon in cell division Control of abscission. Cell Cycle 2009; 8 (4):549-555. PubMed.
Calleja V, Laguerre M, Parker PJ, Larijani B. Role of a Novel PH-Kinase Domain Interface in PKB/Akt Regulation: Structural Mechanism for Allosteric Inhibition. PLoS Biol 2009; 7 (1):189-200. PubMed.
2008
Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B. HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells. PLoS One 2008; 3 (8):e2881. UKPubMed (open access); PubMed; DOI: 10.1371/journal.pone.0002881.
Kermorgant S, Parker PJ. Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol 2008; 182 (5):855-863. UKPubMed (open access); PubMed; DOI: 10.1083/jcb.200806076.
Lanigan PMP, Chan K, Ninkovic T, Templer RH, French PMW, de Mello AJ, Willison KR, Parker PJ, Neil MAA, Ces O, Klug DR. Spatially selective sampling of single cells using optically trapped fusogenic emulsion droplets: a new single-cell proteomic tool. J R Soc Interface 2008; 5 (Supp 2):S161-S168. UKPubMed (open access); PubMed; DOI: 10.1098/rsif.2008.0249.focus.
Saurin AT, Durgan J, Cameron AJ, Faisal A, Marber MS, Parker PJ. The regulated assembly of a PKC epsilon complex controls the completion of cytokinesis. Nat Cell Biol 2008; 10 (8):891-901. PubMed; DOI: 10.1038/ncb1749.
Cameron AJ, Procyk KJ, Leitges M, Parker PJ. PKC alpha protein but not kinase activity is critical for glioma cell proliferation and survival. Int J Cancer 2008; 123 (4):769-779. PubMed.
Verma SK, Ganesan TS, Parker PJ. The tumour suppressor RASSF1A is a novel substrate of PKC. FEBS Lett 2008; 582 (15):2270-2276. PubMed; DOI: 10.1016/j.febslet.2008.05.028.
Faisal A, Saurin A, Gregory B, Foxwell B, Parker PJ. The scaffold MyD88 acts to couple protein kinase C epsilon to toll-like receptors. J Biol Chem 2008; 283 (27):18591-18600. PubMed.
Durgan J, Cameron AJ, Saurin AI, Hanrahan S, Totty N, Messing RO, Parker PJ. The identification and characterization of novel PKC epsilon phosphorylation sites provide evidence for functional cross-talk within the PKC superfamily. Biochem J 2008; 411 (Pt 2):319-331. PubMed.
Jefferies HBJ, Cooke FT, Jat P, Boucheron C, Koizumi T, Hayakawa M, Kaizawa H, Ohishi T, Workman P, Waterfield MD, Parker PJ. A selective PIKfyve inhibitor blocks PtdIns(3,5) P-2 production and disrupts endomembrane transport and retroviral budding. EMBO Rep 2008; 9 (2):164-170. UKPubMed (open access); PubMed; DOI: 10.1038/sj.embor.7401155.
Osborne SL, Wen PJ, Boucheron C, Nguyen HN, Hayakawa M, Kaizawa H, Parker PJ, Vitale N, Meunier FA. PIKfyve negatively regulates exocytosis in neurosecretory cells. J Biol Chem 2008; 283 (5):2804-2813. PubMed.
2007
Cameron AJ, De Rycker M, Calleja V, Alcor D, Kjaer S, Kostelecky B, Saurin A, Faisal A, Laguerre M, Hemmings BA, McDonald N, Larijani B, Parker PJ. Protein kinases, from B to C. Biochem Soc Trans 2007; 35 (Pt 5):1013-1017.
Durgan J, Michael N, Totty N, Parker PJ. Novel phosphorylation site markers of protein kinase C delta activation. FEBS Lett 2007; 581 (18):3377-3381.
Hayakawa M, Kawaguchi KI, Kaizawa H, Tomonobu KAAA, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Parker P, Workman P, Waterfield MD. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110 alpha inhibitors. Bioorg Med Chem 2007; 15 (17):5837-5844.
Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Bjerke LM, Kelland L, Valenti M, Patterson L, Gowan S, Brandon AD, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Patel S, Saghir N, Parker P, Waterfield M, Workman P. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007; 67 (12):5840-5850.
Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Workman P, Waterfield MD, Parker P. Synthesis and biological evaluation of pyrido[3',2': 4,5]furo [3,2-d]pyrimidine derivatives as novel PI3 kinase p110 alpha inhibitors. Bioorg Med Chem Lett 2007; 17 (9):2438-2442.
Iturrioz X, Parker PJ. PKC zeta II is a target for degradation through the tumour suppressor protein pVHL. FEBS Lett 2007; 581 (7):1397-1402.
Calleja V, Alcor D, Laguerre M, Park J, Vojnovic B, Hemmings BA, Downward J, Parker PJ, Larijani B. Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol 2007; 5 (4):780-791.
Hsieh HL, Wang HH, Wu CY, Jou MJ, Yen MH, Parker P, Yang CM. BK-induced COX-2 expression via PKC-delta-dependent activation of p42/p44 MAPK and NF-kappa B in astrocytes. Cell Signal 2007; 19 (2):330-340.
Byrne RD, Rosivatz E, Parsons M, Larijani B, Parker PJ, Ng T, Woscholski R. Differential activation of the PI 3-kinase effectors AKT/PKB and p70 S6 kinase by compound 48/80 is mediated by PKCalpha. Cell Signal 2007; 19 (2):321-329. DOI: 10.1016/j.cellsig.2006.07.004.
Hayakawa M, Kaizawa H, Kawaguchi K, Ishikawa N, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Waterfield MD, Parker P, Workman P. Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110 alpha inhibitors. Bioorg Med Chem 2007; 15 (1):403-412.
2006
Fili N, Calleja V, Woscholski R, Parker PJ, Larijani B. Compartmental signal modulation: Endosomal phosphatidylinositol 3-phosphate controls endosome morphology and selective cargo sorting. Proc Natl Acad Sci U S A 2006; 103 (42):15473-15478. DOI: 10.1073/pnas.0607040103.
Phelan JP, Millson SH, Parker PJ, Piper PW, Cooke FT. Fab1p and AP-1 are required for trafficking of endogenously ubiquitylated cargoes to the vacuole lumen in S. cerevisiae. J Cell Sci 2006; 119 (20):4225-4234.
Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Okada M, Ohta M, Tsukamoto S, Parker P, Workman P, Waterfield M. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 2006; 14 (20):6847-6858.
Pardo OE, Wellbrock C, Khanzada UK, Aubert M, Arozarena I, Davidson S, Bowen F, Parker PJ, Filonenko VV, Gout IT, Sebire N, Marais R, Downward J, Seckl MJ. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKC epsilon, B-Raf and S6K2. EMBO J 2006; 25 (13):3078-3088.
Iturrioz X, Durgan J, Calleja V, Larijani B, Okuda H, Whelan R, Parker PJ. The von Hippel-Lindau tumour-suppressor protein interaction with protein kinase C delta. Biochem J 2006; 397 (Pt 1):109-120.
Muqit MMK, Abou-Sleiman PM, Saurin AT, Harvey K, Gandhi S, Deas E, Eaton S, Payne Smith MD, Venner K, Matilla A, Healy DG, Gilks WP, Lees AJ, Holton J, Revesz T, Parker PJ, Harvey RJ, Wood NW, Latchman DS. Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem 2006; 98 (1):156-169.
Sipeki S, Bander E, Parker PJ, Farago A. PKC alpha reduces the lipid kinase activity of the p110 alpha/p85 alpha PI3K through the phosphorylation of the catalytic subunit. Biochem Biophys Res Commun 2006; 339 (1):122-125.
Hsieh H-L, Wu C-Y, Hwang T-L, Yen M-H, Parker P, Yang C-M. BK-induced cytosolic phospholipase A(2) expression via sequential PKC-delta, p42/p44 MAPK, and NF-kappa B activation in rat brain astrocytes. J Cell Physiol 2006; 206 (1):246-254. DOI: 10.1002/jcp.20457.
Kong A, Leboucher P, Leek R, Calleja V, Winter S, Harris A, Parker PJ, Larijani B. Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Res 2006; 66 (5):2834-2843.
2005
Ivaska J, Vuoriluoto K, Huovinen T, Izawa I, Inagaki M, Parker PJ. PKC epsilon-mediated phosphorylation of vimentin controls integrin recycling and motility. EMBO J 2005; 24 (22):3834-3845.
Meunier FA, Osborne SL, Hammond GRV, Cooke FT, Parker PJ, Domin J, Schiavo G. Phosphatidylinositol 3-kinase C2 alpha is essential for ATP-dependent priming of neurosecretory granule exocytosis. Mol Biol Cell 2005; 16 (10):4841-4851. DOI: 10.1091/mbc.E05-02-0171.
Bartlett S, Beddard GS, Jackson RM, Kayser V, Kilner C, Leach A, Nelson A, Oledzki PR, Parker P, Reid GD, Warriner SL. Comparison of the ATP binding sites of protein kinases using conformationally diverse bisindolylmaleimides. J Am Chem Soc 2005; 127 (33):11699-11708.
Kermorgant S, Parker PJ. c-met signalling: spatio-temporal decisions. Cell Cycle 2005; 4 (3):352-355.
Hemmings B, Parker P. Cell regulation. Curr Opin Cell Biol 2005; 17 (2):105-106.
2004
Parker PJ. The ubiquitous phosphoinositides. Biochem Soc Trans 2004; 32 (6):893-898.
Sundberg C, Thodeti CK, Kveiborg M, Larsson C, Parker P, Albrechtsen R, Wewer UM. Regulation of ADAM12 cell-surface expression by protein kinase C epsilon. J Biol Chem 2004; 279 (49):51601-51611.
Kermorgant S, Zicha D, Parker PJ. PKC controls HGF-dependent c-Met traffic, signalling and cell migration. EMBO J 2004; 23 (19):3721-3734.
Jeffries TR, Dove SK, Michell RH, Parker PJ. PtdIns-specific MPR pathway association of a novel WD40 repeat protein, WIPI49. Mol Biol Cell 2004; 15 (6):2652-2663.
Dove SK, Piper RC, McEwen RK, Yu JW, King MC, Hughes DC, Thuring J, Holmes AB, Cooke FT, Michell RH, Parker PJ, Lemmon MA. Svp1p defines a family of phosphatidylinositol 3,5-bisphosphate effectors. EMBO J 2004; 23 (9):1922-1933.
Parkinson SJ, Le Good JA, Whelan RDH, Whitehead P, Parker PJ. Identification of PKC zeta II: an endogenous inhibitor of cell polarity. EMBO J 2004; 23 (1):77-88.
Parker PJ, Murray-Rust J. PKC at a glance. J Cell Sci 2004; 117 (2):131-132.
2003
Parker PJ. Protein kinase C phosphorylation: an introduction. Methods Mol Biol 2003; 233 :159-162.
Tan SL, Parker PJ. Emerging and diverse roles of protein kinase C in immune cell signalling. Biochem J 2003; 376 (Pt 3):545-552.
Poyurovsky MV, Jacq X, Ma C, Karni-Schmidt O, Parker PJ, Chalfie M, Manley JL, Prives C. Nucleotide binding by the MDM2 RING domain facilitates Arf-independent MDM2 nucleolar localization. Mol Cell 2003; 12 (4):875-887.
Torbett NE, Casamassima A, Parker PJ. Hyperosmotic-induced protein kinase N 1 activation in a vesicular compartment is dependent upon Rac1 and 3-phosphoinositide-dependent kinase 1. J Biol Chem 2003; 278 (34):32344-32351.
Kermorgant S, Zicha D, Parker PJ. Protein kinase C controls microtubule-based traffic but not proteasomal degradation of c-Met. J Biol Chem 2003; 278 (31):28921-28929.
Mostafavi-Pour Z, Askari JA, Parkinson SJ, Parker PJ, Ng TTC, Humphries MJ. Integrin-specific signaling pathways controlling focal adhesion formation and cell migration. J Cell Biol 2003; 161 (1):155-167.
Ivaska J, Bosca L, Parker PJ. PKC epsilon is a permissive link in integrin-dependent IFN-gamma signalling that facilitates JAK phosphorylation of STAT1. Nat Cell Biol 2003; 5 (4):363-369.
Ivaska J, Kermorgant S, Whelan R, Parsons M, Ng T, Parker PJ. Integrin-protein kinase C relationships. Biochem Soc Trans 2003; 31 (Pt 1):90-93.
Valovka T, Verdier F, Cramer R, Zhyvoloup A, Fenton T, Rebholz H, Wang ML, Gzhegotsky M, Lutsyk A, Matsuka G, Filonenko V, Wang LJ, Proud CG, Parker PJ, Gout IT. Protein kinase C phosphorylates ribosomal protein S6 kinase beta II and regulates its subcellular localization. Mol Cell Biol 2003; 23 (3):852-863.
Castrillo A, Traves PG, Martin-Sanz P, Parkinson S, Parker PJ, Bosca L. Potentiation of protein kinase C zeta activity by 15-deoxy-Delta(12,14)-prostaglandin J(2) induces an imbalance between mitogen-activated protein kinases and NF-kappa B that promotes apoptosis in macrophages. Mol Cell Biol 2003; 23 (4):1196-1208.
Owen D, Lowe PN, Nietlispach D, Brosnan CE, Chirgadze DY, Parker PJ, Blundell TL, Mott HR. Molecular dissection of the interaction between the small G proteins Rac1 and RhoA and protein kinase C-related kinase 1 (PRK1). J Biol Chem 2003; 278 (50):50578-50587.
2002
Srivastava J, Procyk KJ, Iturrioz X, Parker PJ. Phosphorylation is required for PMA- and cell-cycle-induced degradation of protein kinase C delta. Biochem J 2002; 368 (Pt 1):349-355.
Desrivieres S, Cooke FT, Morales-Johansson H, Parker PJ, Hall MN. Calmodulin controls organization of the actin cytoskeleton via regulation of phosphatidylinositol (4,5)-bisphosphate synthesis in Saccharomyces cerevisiae. Biochem J 2002; 366 (Pt 3):945-951.
Parsons M, Keppler MD, Kline A, Messent A, Humphries MJ, Gilchrist R, Hart IR, Quittau-Prevostel C, Hughes WE, Parker PJ, Ng T. Site-directed perturbation of protein kinase C-integrin interaction blocks carcinoma cell chemotaxis. Mol Cell Biol 2002; 22 (16):5897-5911.
Ivaska J, Whelan RDH, Watson R, Parker PJ. PKC epsilon controls the traffic of beta 1 integrins in motile cells. EMBO J 2002; 21 (14):3608-3619.
Srivastava J, Goris J, Dilworth SM, Parker PJ. Dephosphorylation of PKC delta by protein phosphatase 2Ac and its inhibition by nucleotides. FEBS Lett 2002; 516 (1-3):265-269.
Hughes WE, Larijani B, Parker PJ. Detecting protein-phospholipid interactions: epidermal growth factor-induced activation of phospholipase D1b in situ. J Biol Chem 2002; 277 (25):22974-22979.
Arnott CH, Scott KA, Moore RJ, Hewer A, Phillips DH, Parker P, Balkwill FR, Owens DM. Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. Oncogene 2002; 21 (31):4728-4738.
Other publications
Cameron AJ, Parker PJ. Protein kinase C ¿ A family of protein kinases, allosteric effectors or both? Adv Enzyme Regul 2009; doi10.1016
Roffey J, Rosse C, Linch M, Hibbert A, McDonald NQ, Parker PJ. Protein kinase C intervention-the state of play. Curr Opin Cell Biol 2009; 21(2):268-279.
|
